We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the terms of the deal, Tocagen will receive $16M upfront, $4M in near-term milestones, up to $111M in future milestones and tiered low double-digit royalties on net sales.
Tocagen Inc. today announced the EMA has granted orphan medicinal product designation to Toca 511 (vocimagene amiretrorepvec) & Toca FC for the treatment of patients with glioma, a type of brain tumor.